ArticleInfectious diseases and therapy2014
Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection.
Article in Infectious diseases and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Systematic review of guidelines for the diagnosis and treatment of Clostridioides difficile infection.Frontiers in cellular and infection microbiology · 2022Pooled it
- Genomic insights into tigecycline non-susceptibility in Clostridioides difficile: the role of the Tet P determinant and efflux mechanisms.BMC microbiology · 2025Article
- Management of severe and fulminantJournal of medical microbiology · 2025Review
- Review
- [Clostridium difficile in the intensive care unit].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2020Review
- Treatment of Severe and Fulminnant Clostridioides difficile Infection.Current treatment options in gastroenterology · 2019Review
- Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Observational
- Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness.Journal of clinical medicine · 2018Article
- Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2018Review
- Sleeping with the enemy: Clostridium difficile infection in the intensive care unit.Critical care (London, England) · 2017Review
- Toxic Megacolon - A Three Case Presentation.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2017Article
- Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, NonoperativeOpen forum infectious diseases · 2017Article
- [Clostridium difficile infections in geriatric patients].Zeitschrift fur Gerontologie und Geriatrie · 2016Review
- [Clostridium difficile infection : What is currently available for treatment?]Der Internist · 2016Article
- Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.Antibiotics (Basel, Switzerland) · 2015Review
- Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Intensive care medicine · 2015Review
- Leaping Forward in the Treatment ofGE Portuguese journal of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionClostridium difficile infection (CDI) is a common cause of nosocomial diarrhea. Metronidazole and vancomycin are the primary treatment options for CDI, but increasing rates of antimicrobial resistance and severe, refractory disease have prompted the need for alternative agents. Tigecycline has previously demonstrated favorable in vitro activity against C. difficile isolates, but clinical data on its use in the treatment of CDI are severely lacking. The objective of this study was to describe our experience using tigecycline in the treatment of severe and severe complicated CDI.
methodsThis was a retrospective case series of hospitalized patients with severe and severe complicated CDI who were treated with tigecycline. Disease severity assessments were determined according to current practice guidelines. Diagnosis of toxigenic CDI was confirmed by polymerase chain reaction and patients were excluded if they received tigecycline for <48 h. Data were collected by review of the electronic medical record. The primary outcome was clinical cure. Secondary outcomes were sustained response, hospital mortality, and 28-day all-cause mortality.
resultsA total of 7 cases of severe and complicated CDI were reviewed. Intravenous tigecycline administered as a 100-mg loading dose followed by 50 mg twice daily resulted in clinical cure in 85.7% (n = 6/7) of cases. The majority of patients (n = 4/5) were treated with the novel triple therapy combination of tigecycline, vancomycin, and metronidazole and resulted in clinical cure in 80% (n = 4/5) cases. Sustained response at 28 days was 100% among evaluable cases (n = 5/5). Hospital mortality did not occur in any patients, and 28-day all-cause mortality was 28.6% (n = 2/7).
conclusionTigecycline appears to be a reasonable addition to the therapeutic regimen in the treatment of severe or complicated CDI, including cases that are refractory to standard therapy. A prospective clinical trial confirming these observational findings is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.